Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity-Reference-Cited by-同舟云学术

Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity

Published:2022-07-20 Issue:14 Volume:135 Page:1716-1727
ISSN:0366-6999
Container-title:Chinese Medical Journal
language:en
Short-container-title:

Author:

Liu Zuojing,Zhu Shiwei,He Meibo,Li Mo,Wei Hui,Zhang Lu,Sun Qinghua,Jia Qiong,Hu Nan,Fang Yuan,Song Lijin,Zhou Chen,Tao Heqing,Kao John Y,Zhu Huaiqiu,Owyang Chung,Duan Liping

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,General Medicine

Reference43 articles.

1. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis;Lovell;Clin Gastroenterol Hepatol,2012

2. A meta-analysis of the prevalence and risk factors of irritable bowel syndrome in Chinese community (in Chinese);Zhang;Chin J Intern Med,2014

3. Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies;Shah;Am J Gastroenterol,2020

4. ACG clinical guideline: small intestinal bacterial overgrowth;Pimentel;Am J Gastroenterol,2020

5. Lactulose breath testing as a predictor of response to rifaximin in patients with irritable bowel syndrome with diarrhea;Rezaie;Am J Gastroenterol,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differences in clinical manifestations and the fecal microbiome between irritable bowel syndrome and small intestinal bacterial overgrowth;Digestive and Liver Disease;2024-07

2. Fecal Coprococcus, hidden behind abdominal symptoms in patients with small intestinal bacterial overgrowth;Journal of Translational Medicine;2024-05-25

3. Fecal Coprococcus, Hidden behind Abdominal Symptoms in Patients with Small Intestinal Bacterial Overgrowth;2024-01-03

4. Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota;World Journal of Gastroenterology;2023-07-21

5. “Sentinel or accomplice”: gut microbiota and microglia crosstalk in disorders of gut–brain interaction;Protein & Cell;2023-04-19